Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.71 |
| ▸ | CA9 | Q16790 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.69 |
| ▸ | CASP3 | P42574 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.69 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.69 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | AR | P10275 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203685 | 0.88 | MAOB (0.83) | MAOBMAOA | |
| SCHEMBL4213219 | 0.87 | CYP19A1 (0.66) | MAOB | |
| SCHEMBL4209951 | 0.85 | MAOB (0.66) | CA12CA9MAOBNPC1MAOA | |
| SCHEMBL4211377 | 0.85 | MAOB (0.68) | CA12CA9MAOBNPC1MAOA | |
| SCHEMBL29116822 | 0.83 | MAOB (0.74) | CA12CA9MAOBNPC1MAOA | |
| SCHEMBL17931588 | 0.82 | MAOB (0.74) | MAOBNPC1MAOACASP3RAB9A | |
| SCHEMBL29382160 | 0.82 | MAOB (1.00) | CA12MAOBNPC1MAOACASP3 | |
| SCHEMBL7549311 | 0.82 | MAOB (0.72) | CA12CA9MAOBNPC1MAOA | |
| SCHEMBL107774 | 0.82 | MAOB (1.00) | CA12MAOBNPC1MAOACASP3 | |
| SCHEMBL27704558 | 0.81 | MAOB (0.61) | CA12CA9MAOBNPC1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3039009-B1 | MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | UNIV BRITISH COLUMBIA (CA) | 2019-05-01 | — | — | EP | disclosed |
| EP-3039009-B1 | MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | UNIV BRITISH COLUMBIA (CA) | 2019-05-01 | — | — | EP | disclosed |
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-02-05 | — | — | US | disclosed |
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-21 | — | — | US | disclosed |
| EP-3039009-A1 | MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | The University of British Columbia (CA) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015027324-A1 | MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-03-05 | — | — | WO | disclosed |
| WO-2015027324-A1 | MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-03-05 | — | — | WO | disclosed |
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-01-01 | — | — | US | disclosed |
| CN-101137638-A | Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives | NEWRON PHARM SPA (IT) | 2008-03-05 | — | — | CN | disclosed |
| EP-1863784-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006102958-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | MAOB, MAOA, COMT | CA12 2206/4885CA9 1136/4885MAOB 1/4885 |
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | MAOB, MAOA, AOC3 | CA12 4561/4885CA9 3414/4885MAOB 1/4885 |
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | MAOB, MAOA, COMT | CA12 2206/4885CA9 1136/4885MAOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.